VYNE Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de VYNE Therapeutics' es Dave Domzalski , nombrado en Mar 2020, tiene una permanencia de 4.08 años. compensación anual total es $2.72M, compuesta por 23.5% salario y 76.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.5% de las acciones de la empresa, por valor de $1.22M. La antigüedad media del equipo directivo y de la junta directiva es de 4.1 años y 3 años, respectivamente.
Información clave
Dave Domzalski
Chief Executive Officer (CEO)
US$2.7m
Compensación total
| Porcentaje del salario del CEO | 23.5% |
| Permanencia del CEO | 4.2yrs |
| Participación del CEO | 3.5% |
| Permanencia media de la dirección | 4.2yrs |
| Promedio de permanencia en la Junta Directiva | 3.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation
Apr 27
We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate
May 04VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M
Aug 12Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky
Jul 02VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely
Mar 19VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan
Jan 13VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely
Dec 03Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13VYNE Therapeutics: Terrible Depreciation Of Shareholder Value
Jun 30Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt
Jun 07Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts
Feb 17
Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)
Feb 10VYNE Therapeutics closes capital raise of $50M
Jan 29What Is The Ownership Structure Like For VYNE Therapeutics Inc. (NASDAQ:VYNE)?
Jan 06VYNE Therapeutics reports successful FDA meeting for FCD105 in acne
Dec 17Have Insiders Been Buying VYNE Therapeutics Inc. (NASDAQ:VYNE) Shares?
Dec 08Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$29m |
| Dec 31 2023 | US$3m | US$638k | -US$28m |
| Sep 30 2023 | n/a | n/a | -US$29m |
| Jun 30 2023 | n/a | n/a | -US$33m |
| Mar 31 2023 | n/a | n/a | -US$31m |
| Dec 31 2022 | US$1m | US$638k | -US$34m |
| Sep 30 2022 | n/a | n/a | -US$35m |
| Jun 30 2022 | n/a | n/a | -US$40m |
| Mar 31 2022 | n/a | n/a | -US$42m |
| Dec 31 2021 | US$5m | US$638k | -US$44m |
| Sep 30 2021 | n/a | n/a | -US$59m |
| Jun 30 2021 | n/a | n/a | -US$69m |
| Mar 31 2021 | n/a | n/a | -US$226m |
| Dec 31 2020 | US$3m | US$501k | -US$256m |
| Sep 30 2020 | n/a | n/a | -US$270m |
| Jun 30 2020 | n/a | n/a | -US$269m |
| Mar 31 2020 | n/a | n/a | -US$120m |
| Dec 31 2019 | n/a | n/a | -US$95m |
| Sep 30 2019 | n/a | n/a | -US$71m |
| Jun 30 2019 | n/a | n/a | -US$64m |
| Mar 31 2019 | n/a | n/a | -US$63m |
| Dec 31 2018 | US$1m | US$440k | -US$74m |
| Sep 30 2018 | n/a | n/a | -US$77m |
| Jun 30 2018 | n/a | n/a | -US$80m |
| Mar 31 2018 | n/a | n/a | -US$77m |
| Dec 31 2017 | US$3m | US$417k | -US$66m |
Compensación vs. Mercado: La compensación total de Dave($USD2.72M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).
Compensación vs. Ingresos: La compensación de Dave ha aumentado mientras la empresa no es rentable.
CEO
Dave Domzalski (56 yo)
4.2yrs
Permanencia
US$2,716,350
Compensación
Mr. David T. Domzalski, also known as Dave, has been President, Chief Executive Officer and Director at VYNE Therapeutics Inc. (formerly known as Menlo Therapeutics Inc.). since March 9, 2020. Mr. Domzalsk...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 4.2yrs | US$2.72m | 3.5% $ 1.3m | |
| Chief Scientific Officer | 4.2yrs | US$1.16m | 0.95% $ 354.4k | |
| General Counsel | 4.2yrs | US$1.13m | 1.06% $ 395.6k | |
| CFO & Treasurer | 2.9yrs | sin datos | 0.93% $ 349.1k | |
| Consultant | 5.5yrs | US$115.20k | sin datos |
4.2yrs
Permanencia media
50yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de VYNE se considera experimentado (4.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 4.2yrs | US$2.72m | 3.5% $ 1.3m | |
| Lead Independent Director | 3.7yrs | US$123.60k | 0.26% $ 96.7k | |
| Director | 8.7yrs | US$83.60k | 0.053% $ 19.7k | |
| Independent Non-Employee Director | 4.2yrs | US$101.10k | 0.013% $ 5.0k | |
| Independent Director | 5.2yrs | US$108.60k | 0% $ 0 | |
| Independent Director | less than a year | sin datos | sin datos | |
| Independent Non Employee Director | 4.2yrs | US$116.10k | 0.0074% $ 2.8k | |
| Member of Scientific Advisory Board | 2.6yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.6yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.6yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.6yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.6yrs | sin datos | sin datos |
3.1yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de VYNE se considera experimentada (3 años de antigüedad promedio).